Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/216321
Title: | Continuous and differential improvement in worldwide access to hematopoietic cell transplantation: activity has doubled in a decade with a notable increase in unrelated and non-identical related donors |
Author: | Atsuta, Yoshiko Baldomero, Helen Neumann, Daniel Sureda, Anna Devos, Jakob D. Iida, Minako Karduss, Amado Purtill, Duncan Elhaddad, Alaa M. Bazuaye, Nosa G. Bonfim, Carmem De La Camara, Rafael Chaudhri, Naeem A. Ciceri, Fabio Correa, Cinthya Frutos, Cristobal Galeano, Sebastian Garderet, Laurent Gonzalez Ramella, Oscar Greco, Raffaella Hamad, Nada Hazenberg, Mette D. Horowitz, Mary M. Kalwak, Krzysztof Ko, Bor-Sheng Kodera, Yoshihisa Koh, Mickey B.C. Liu, Kaiyan McLornan, Donal P. Moon, Joon Ho Neven, Benedicte Okamoto, Shinichiro Pasquini, Marcelo C. Passweg, Jakob R. Paulson, Kristjan Rondelli, Damiano Ruggeri, Annalisa Seber, Adriana Snowden, John A. Srivastava, Alok Szer, Jeff Weisdorf, Daniel Worel, Nina Greinix, Hildegard Saber, Wael Aljurf, Mahmoud Niederwieser, Dietger |
Keywords: | Hematopoesi Malalties hematològiques Hematopoiesis Hematologic diseases |
Issue Date: | 9-May-2024 |
Publisher: | Ferrata Storti Foundation (Haematologica) |
Abstract: | Promoting access to and excellence in hematopoietic cell transplantation (HCT) by collecting and disseminating data on global HCT activities is one of the principal activities of the Worldwide Network for Blood and Marrow Transplantation, a non-governmental organization in working relations with the World Health Organization. HCT activities are recorded annually by member societies, national registries and individual centers including indication, donor type (allogeneic/autologous), donor match and stem cell source (bone marrow/peripheral blood stem cells/cord blood). In 2018, 1,768 HCT teams in 89 countries (6 World Health Organization regions) reported 93,105 (48,680 autologous and 44,425 allogeneic) HCT. Major indications were plasma cell disorders and lymphoma for autologous, and acute leukemias and MDS/MPN for allogeneic HCT. HCT numbers increased from 48,709 in 2007. Notable increases were seen for autoimmune diseases in autologous and hemoglobinopathies in allogeneic HCT. The number of allogeneic HCT more than doubled with significant changes in donor match. While HCT from HLA-identical siblings has seen only limited growth, HCT from non-identical related donors showed significant increase worldwide. Strongest correlation between economic growth indicator of gross national income/capita and HCT activity/10 million population was observed for autologous HCT (correlation coefficient [r]=0.79). HCT from unrelated donors showed strong correlation (r=0.68), but only moderate correlation was detected from related donors (r=0.48 for HLA-identical sibling; r=0.45 for other). The use of HCT doubled in about a decade worldwide at different speed and with significant changes regarding donor match as a sign of improved access to HCT worldwide. Although narrowing, significant gaps remain between developing and non-developing countries. |
Note: | Reproducció del document publicat a: https://doi.org/10.3324/haematol.2024.285002 |
It is part of: | Haematologica, 2024, vol. 109, num. 10, p. 3282-3294 |
URI: | https://hdl.handle.net/2445/216321 |
Related resource: | https://doi.org/10.3324/haematol.2024.285002 |
ISSN: | 1592-8721 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
11584-Article Text-84308-2-10-20240925 (1).pdf | 2.67 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License